Fulvestrant
别名: ICI-182780, ZD 9238, ZM 182780
中文名称:氟维司琼,氟维司群
目录号:S1191 Purity: 99.97%
Fulvestrant是一种Estrogen receptor(ER)拮抗剂, 无细胞试验中IC50为0.094 nM。Fulvestrant还可诱导自噬和凋亡并具有抗肿瘤的活性。
CAS: 129453-61-8
客户使用Selleck的Fulvestrant发表文献164篇
- Signal Transduct Target Ther, 2023 8(1):94
- Cancer Discov, 2021 candisc.1265.2020
- Cancer Cell, 2020 S1535-6108(20)30427-X
- Cancer Discov, 2019 10.1158/2159-8290.CD-18-0830
- Nat Mater, 2018 17(4):361-368
- Cancer Discov, 2018 8(3):336-353
- Eur Respir J, 2017 50(2)
- Nat Genet, 2013 45(12):1439-45
- Biochem Biophys Res Commun, 2025 742:151056
- Cancer Lett, 2024 593:216968
- Cell Death Dis, 2024 15(8):590
- Cell Death Dis, 2024 15(7):480
- Cell Rep, 2024 43(5):114174
- Breast Cancer Res, 2024 26(1):56
- Ecotoxicol Environ Saf, 2024 285:117043
- NPJ Breast Cancer, 2024 10(1):38
- NPJ Breast Cancer, 2024 10(1):74
- J Cell Mol Med, 2024 28(9):e18374
- Cancers (Basel), 2024 16(3)678
- Cancers (Basel), 2024 16(2)257
- Sci Rep, 2024 14(1):16030
- Dis Model Mech, 2024 17(10)dmm050900
- J Chromatogr B Analyt Technol Biomed Life Sci, 2024 1251:124419
- Biomater Res, 2024 28:0010
- bioRxiv, 2024 2024.11.11.623139
- Nat Commun, 2023 14(1):3851
- Cell Rep Med, 2023 4(4):101002
- Cell Rep Med, 2023 4(8):101120
- Clin Cancer Res, 2023 29(8):1557-1568
- Cancer Res, 2023 83(19):3284-3304
- J Immunother Cancer, 2023 11(6)e007117
- J Immunother Cancer, 2023 11(9)e007386
- NPJ Breast Cancer, 2023 9(1):48
- NPJ Breast Cancer, 2023 9(1):96
- Biomolecules, 2023 13(6)965
- Cancers -Basel), 2023 15(19)4772
- J Biol Chem, 2023 299(8):105021
- Drug Des Devel Ther, 2023 17:659-673
- Cell Cycle, 2023 10.1080/15384101.2023.2249702
- Cancer Med, 2023 12(18):18931-18945
- Breast Cancer Res Treat, 2023 201(1):43-56
- Cancer Prev Res (Phila), 2023 16(2):65-73
- Behav Neurol, 2023 2023:1857330
- Breast Cancer (Dove Med Press), 2023 15:899-912
- Reprod Biol, 2023 23(2):100766
- Gynecol Endocrinol, 2023 10.1080/09513590.2023.2269248
- J Endocr Soc, 2023 7(10):bvad117
- ProQuest, 2023
- bioRxiv, 2023 2023.08.21.554116
- Nature Communications, 2022 13, 5258
- Nat Commun, 2022 13(1:7160)
- Nat Commun, 2022 13-1:5258
- Cell Rep, 2022 41(11):111821
- Oncogene, 2022 41(29):3705-3718
- Oncogene, 2022 41(27):3524-3538
- Breast Cancer Res, 2022 24(1):88
- NPJ Breast Cancer, 2022 8(1):96
- Mol Cancer Ther, 2022 21(1):48-57
- Mol Cancer Res, 2022 molcanres.0090.2022-1-28 10:45:29.413
- J Pers Med, 2022 12(2)258
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- J Food Biochem, 2022 10.1111/jfbc.14163
- Biochim Biophys Acta Gen Subj, 2022 1866(1):130046
- Nat Commun, 2021 12(1):2940
- Clin Cancer Res, 2021 10.1158/1078-0432.CCR-20-2961
- Clin Cancer Res, 2021 10.1158/1078-0432.CCR-20-3905
- Cancer Res, 2021 81(24):6259-6272
- Cell Death Dis, 2021 12(6):619
- Chemosphere, 2021 287(Pt 3):132244
- Cell Rep, 2021 34(8):108776
- Breast Cancer Res, 2021 23(1):26
- ACS Biomater Sci Eng, 2021 10.1021/acsbiomaterials.0c01803
- Front Pharmacol, 2021 12:731980
- Cancers (Basel), 2021 13(9)2116
- Front Oncol, 2021 11:681530
- Molecules, 2021 26(19)5858
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Theranostics, 2020 10(4):1833-1848
- Breast Cancer Res, 2020 22(1):84
- Mol Oncol, 2020 1
- NPJ Breast Cancer, 2020 6:37
- Cancer Cell Int, 2020 19;20:58
- Oncotarget, 2020 12;11(19):1714-1728
- Am J Cancer Res, 2020 10(11):3721-3736
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Bone, 2020 130:115123
- PLoS One, 2020 15(9):e0239151
- Cell Biochem Funct, 2020 38(1):38-46
- Drug Test Anal, 2020 10.1002/dta.2917
- Evid Based Complement Alternat Med, 2020 2020:2861978
- Am J Transl Res, 2020 12(7):3926-3939
- Mol Cell, 2019 75(6):1103-1116.e9
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-18-4044
- Cancer Res, 2019 79(19):4965-4977
- Cell Chem Biol, 2019 10.1016/j.chembiol.2019.10.009
- Oncogene, 2019 38(1):47-59
- NPJ Precis Oncol, 2019 3:18
- Oxid Med Cell Longev, 2019 10.1155/2019/2985956
- Cancer Sci, 2019 110(4):1420-1430
- Mol Cancer Ther, 2019 10.1158/1535-7163.MCT-19-0284
- Sci Rep, 2019 9(1):13405
- ACS Chem Biol, 2019 14(4):751-757
- ACS Chem Biol, 2019 14(7):1507-1514
- Am J Reprod Immunol, 2019 10.1111/aji.13197
- Naunyn Schmiedebergs Arch Pharmacol, 2019 392(7):879-886
- J Appl Toxicol, 2019 39(2):271-281
- Steroids, 2019 145:23-31
- J Obstet Gynaecol Res, 2019 45(5):1035-1044
- Nat Commun, 2018 9(1):2311
- Proc Natl Acad Sci U S A, 2018 115(11):E2594-E2603
- Mol Syst Biol, 2018 14(2):e7678
- Cell Death Dis, 2018 9(2):21
- Cell Rep, 2018 24(6):1434-1444
- Int J Pharm, 2018 539(1-2):147-156
- Biochim Biophys Acta, 2018 1863(6):625-638
- Cell Physiol Biochem, 2018 47(6):2199-2215
- Comp Biochem Physiol C Toxicol Pharmacol, 2018 204:26-35
- Reproduction, 2018 155(1):73-83
- ACS Appl Mater Interfaces, 2017 9(14):12195-12202
- Int J Biol Sci, 2017 13(4):505-517
- Cell Death Dis, 2017 8(3):e2662
- Cell Rep, 2017 21(10):2796-2812
- Elife, 2017 10.7554/eLife.24523
- Cancer Sci, 2017 108(6):1177-1184
- Oncotarget, 2017 8(5):8459-8474
- Oncotarget, 2017 8(46):80109-80123
- Oncotarget, 2017 8(15):24237-24249
- Mol Pharm, 2017 14(6):1852-1860
- Horm Cancer, 2017 8(5-6):269-285
- Autophagy, 2016 12(9):1593-613
- Oncogene, 2016 10.1038/onc
- Oncoimmunology, 2016 6(9):e1207032
- ACS Chem Biol, 2016 11(4):992-1000
- PLoS One, 2016 11(6):e0157397
- Mol Med Rep, 2016 14(6):5304-5310
- Evid Based Complement Alternat Med, 2016 2016:2615620
- PeerJ, 2016 4:e1640
- J Biomed Res, 2016 30(5):393-410
- Oncotarget, 2015 6(4):2315-30
- Oncotarget, 2015 6(24):20621-35
- Neoplasia, 2015 17(8):625-33
- Biomedicines, 2015 3(2):182-200
- Med Oncol, 2015 32(6):577
- Med Oncol, 2015 32(6):577
- Anal Cell Pathol (Amst), 2015 2015:975495
- Thorac Cancer, 2015 6(6):695-703
- Thoracic Cancer, 2015 6(6):695-703
- Sci Signal, 2014 7(357):ra121
- Life Sci, 2014 110(1):8-14
- Mol Cancer Ther, 2014 13(1):230-8
- Oncotarget, 2014 5(19):9049-64
- Oncotarget, 2014 5(24):12738-52
- Toxicol Sci, 2014 141(1):188-97
- J Clin Invest, 2013 123(10):4329-43
- Mol Cancer Ther, 2013 1158/1535-7163.MCT-13-0012
- Cell Cycle, 2013 12(4):596-605
- PLoS One, 2013 10.1371/journal.pone.0060889
- J Mol Histol, 2013 44(3):347-56
- Curr Cancer Drug Targets, 2013 13(6):698-707
- PLoS One, 2011 6(7):e21112
- Expert Opin Pharmacother, 2010 11(8):1263-76
化学信息&溶解度
分子量 | 606.77 |
分子式 | C32H47F5O3S |
CAS号 | 129453-61-8 |
Smiles | CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 164.8 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 164.8 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 164.8 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 164.8 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 164.8 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5% DMSO
95% Corn oil
浓度:1.25mg/ml
(2.06mM)
操作示例:以1 mL工作液为例,取50μL 25mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
2%DMSO
30%PEG300
2%Tween80
66%ddH2O
浓度:0.4mg/ml
(0.66mM)
操作示例:以 1 mL 工作液为例,取20μL20mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入20μLTween80,混合均匀使其澄清;然后继续加入660μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。